Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/12814
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Grigg, Andrew P | en |
dc.contributor.author | Dauer, R | en |
dc.contributor.author | Thurlow, P J | en |
dc.date.accessioned | 2015-05-16T02:33:30Z | |
dc.date.available | 2015-05-16T02:33:30Z | |
dc.date.issued | 1989-08-01 | en |
dc.identifier.citation | Australian and New Zealand Journal of Medicine; 19(4): 310-4 | en |
dc.identifier.govdoc | 2675811 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/12814 | en |
dc.description.abstract | Factor V inhibitors are uncommon, bleeding manifestations variable and recommendations for management are unclear. We present a patient with non-Hodgkins lymphoma who developed gastrointestinal bleeding and was found to have a Factor V inhibitor. The inhibitor was active against both plasma Factor V and platelet associated Factor V, and was associated with a five-fold increase in platelet associated IgG. Fresh frozen plasma was ineffective in preventing bleeding. Resolution of bleeding was associated with a fall in the levels of the inhibitor and of platelet associated IgG. The patient had no further bleeding episodes nor evidence of progression of his lymphoma, but six months later died as a result of metastatic adenocarcinoma. | en |
dc.language.iso | en | en |
dc.subject.other | Adenocarcinoma.secondary | en |
dc.subject.other | Aged | en |
dc.subject.other | Blood Coagulation Disorders.blood.complications | en |
dc.subject.other | Blood Coagulation Factors.antagonists & inhibitors | en |
dc.subject.other | Blood Platelets.metabolism | en |
dc.subject.other | Factor V Deficiency.blood.complications | en |
dc.subject.other | Gastrointestinal Hemorrhage.blood.etiology | en |
dc.subject.other | Humans | en |
dc.subject.other | Immunoglobulin G.metabolism | en |
dc.subject.other | Leukemia, Lymphocytic, Chronic, B-Cell.complications | en |
dc.subject.other | Male | en |
dc.subject.other | Partial Thromboplastin Time | en |
dc.subject.other | Platelet Factor 3.antagonists & inhibitors | en |
dc.subject.other | Prothrombin Time | en |
dc.title | Bleeding due to an acquired inhibitor of platelet associated factor V. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Australian and New Zealand Journal of Medicine | en |
dc.identifier.affiliation | Austin Hospital, Melbourne, Australia | en |
dc.description.pages | 310-4 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/2675811 | en |
dc.type.austin | Journal Article | en |
local.name.researcher | Grigg, Andrew P | |
item.languageiso639-1 | en | - |
item.openairetype | Journal Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
crisitem.author.dept | Clinical Haematology | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.